Cardiovascular and Other Competing Causes of Death in Male Breast Cancer Patients: A Population-Based Epidemiologic Study

被引:7
作者
Zhang, Hanbin [1 ]
Lin, Wenrui [2 ]
Chen, Dongting [1 ]
Wang, Kenie [3 ]
Tu, Wei [4 ]
Lin, Huiwen [4 ]
Li, Kun [4 ]
Ye, Shangzhu [5 ]
Guan, Tianwang [6 ]
Chen, Yuerong [4 ]
机构
[1] Guangzhou Med Univ, Clin Coll 2, Dept Clin Med, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Med Univ, Clin Coll 6, Dept Clin Med, Guangzhou, Guangdong, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Breast Canc 1, Tianjin, Peoples R China
[4] Guangzhou Univ Chinese Med, Jinshazhou Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China
[5] Yangjiang Hosp Tradit Chinese Med, Dept Ophthalmol & Otorhinolaryngol, Yangjiang, Peoples R China
[6] Southern Med Univ, Zhujiang Hosp, Lab Heart Ctr, Dept Cardiol, Guangzhou, Guangdong, Peoples R China
关键词
male breast cancer; cardio-oncology; elderly patients; cause of death; non cancer death; cardiovascular death; RISK; DISEASE;
D O I
10.2147/CIA.S314689
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Purpose: Male breast cancer (MBC) is a rare disease that tends to occur in elderly men. Little is known about the causes of death in MBC because of the small sample size of most studies. This study aimed to investigate the causes of death in MBC patients. Patients and Methods: MBC patient data were obtained from the Surveillance, Epidemiology, and End Results database (1975-2016). Time trends of MBC mortality in the US population were analyzed using Joinpoint software. We calculated the proportion of each cause of death in the overall cohort and in different patient subgroups. Competing risk models were used to calculate cumulative mortality at different follow-up times. The risk of cardiovascular death (CVD) in MBC patients was compared to that of the age-matched general population by calculating standardized mortality ratio (SMR). Results: In total, 6426 patients were included in the analysis. MBC mortality rate increased between 2004 and 2019 (annual percentage change=1.16, 95% confidence interval [CI]: 0.50, 1.80). There were 1757 patients (27.3%) who died of non-breast cancer causes. CVD was the leading cause of death in patients who were elderly or had localized disease. MBC patients had a 6.58-fold higher risk of CVD than the general population (SMR=6.58, 95% CI: 6.14, 7.05). Conclusion: Non-breast cancer death accounts for the majority of deaths in MBC patients who are elderly or have localized cancer. Compared to the general population, MBC patients have an increased risk of CVD. These results highlight the importance of monitoring cardiovascular comorbidities in MBC patients.
引用
收藏
页码:1393 / 1401
页数:9
相关论文
共 35 条
[1]   How to obtain the P value from a confidence interval [J].
Altman, Douglas G. ;
Bland, J. Martin .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[2]   Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer [J].
Anderson, William F. ;
Jatoi, Ismail ;
Tse, Julia ;
Rosenberg, Philip S. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :232-239
[3]  
[Anonymous], Multiple causes of death 1999-2018. Data from CDC Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database
[4]   Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer [J].
Bardia, Aditya ;
Arieas, Erin T. ;
Zhang, Zhe ;
DeFilippis, Andrew ;
Tarpinian, Karineh ;
Jeter, Stacie ;
Anne Nguyen ;
Henry, N. Lynn ;
Flockhart, David A. ;
Hayes, Daniel F. ;
Hayden, Jill ;
Storniolo, Anna Maria ;
Armstrong, Deborah K. ;
Davidson, Nancy E. ;
Fetting, John ;
Ouyang, Pamela ;
Wolff, Antonio C. ;
Blumenthal, Roger S. ;
Ashen, M. Dominique ;
Stearns, Vered .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (03) :907-914
[5]  
Breslow N E, 1987, IARC Sci Publ, P1
[6]   Racial disparities in treatment and survival of male breast cancer [J].
Crew, Katherine D. ;
Neugut, Alfred I. ;
Wang, Xiaoyan ;
Jacobson, Judith S. ;
Grann, Victor R. ;
Raptis, George ;
Hershman, Dawn L. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) :1089-1098
[7]  
Donegan WL, 1998, CANCER-AM CANCER SOC, V83, P498, DOI 10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO
[8]  
2-R
[9]   Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis [J].
Eggemann, Holm ;
Brucker, Cosima ;
Schrauder, Michael ;
Thill, Marc ;
Flock, Felix ;
Reinisch, Mattea ;
Costa, Serban-Dan ;
Ignatov, Atanas .
BRITISH JOURNAL OF CANCER, 2020, 123 (01) :33-37
[10]   Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis [J].
Eggemann, Holm ;
Bernreiter, Anna-Lena ;
Reinisch, Mattea ;
Loibl, Sibylle ;
Taran, Florin-Andrei ;
Costa, Serban-Dan ;
Ignatov, Atanas .
BRITISH JOURNAL OF CANCER, 2019, 120 (03) :301-305